
## Simone Hettmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7999228/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
2	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
3	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
4	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. Cancer Cell, 2014, 26, 273-287.	16.8	152
5	Muscling in: Uncovering the origins of rhabdomyosarcoma. Nature Medicine, 2010, 16, 171-173.	30.7	112
6	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
7	Anaplastic rhabdomyosarcoma in <i>TP53</i> germline mutation carriers. Cancer, 2014, 120, 1068-1075.	4.1	93
8	Rictor/mTORC2 Loss in the Myf5 Lineage Reprograms Brown Fat Metabolism and Protects Mice against Obesity and Metabolic Disease. Cell Reports, 2014, 8, 256-271.	6.4	92
9	Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes and Development, 2014, 28, 1578-1591.	5.9	87
10	Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proceedings of the United States of America, 2011, 108, 20002-20007.	7.1	66
11	Isolation of Progenitors that Exhibit Myogenic/Osteogenic Bipotency InÂVitro by Fluorescence-Activated Cell Sorting from Human Fetal Muscle. Stem Cell Reports, 2014, 2, 92-106.	4.8	64
12	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a025650-a025650.	6.2	60
13	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer, 2019, 66, e27869.	1.5	57
14	Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. ELife, 2015, 4, .	6.0	56
15	A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development (Cambridge), 2013, 140, 2354-2364.	2.5	53
16	Efficient Generation of iPS Cells from Skeletal Muscle Stem Cells. PLoS ONE, 2011, 6, e26406.	2.5	50
17	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precision Oncology, 2018, 2, 1-16.	3.0	41
18	Synovial Sarcoma in Children: Imaging Features and Common Benign Mimics. American Journal of Roentgenology, 2010, 195, 1026-1032.	2.2	38

SIMONE HETTMER

#	Article	IF	CITATIONS
19	Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma. PLoS Genetics, 2014, 10, e1004107.	3.5	38
20	Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2021, 68, e28798.	1.5	38
21	Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Letters, 2005, 225, 141-149.	7.2	37
22	An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Populationâ€Based Evidence for a Cancer Predisposition Syndrome?. Pediatric Blood and Cancer, 2016, 63, 196-201.	1.5	35
23	Mutations in Hedgehog pathway genes in fetal rhabdomyomas. Journal of Pathology, 2013, 231, 44-52.	4.5	32
24	Epithelioid hemangioendotheliomas of the liver and lung in children and adolescents. Pediatric Blood and Cancer, 2017, 64, e26675.	1.5	31
25	Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. European Journal of Cancer, 2020, 137, 183-192.	2.8	28
26	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 2021, 13, 1151.	3.7	27
27	Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Medicine, 2015, 4, 781-790.	2.8	25
28	Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression. Cancer Research, 2003, 63, 7270-6.	0.9	25
29	Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells. Human Immunology, 2005, 66, 95-103.	2.4	24
30	Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open, 2019, 4, e000583.	4.5	22
31	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer, 2020, 126, 4032-4041.	4.1	20
32	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. European Journal of Cancer, 2022, 172, 367-386.	2.8	19
33	Myogenic Tumors in Nevoid Basal Cell Carcinoma Syndrome. Journal of Pediatric Hematology/Oncology, 2015, 37, 147-149.	0.6	18
34	RhabdomyosarcomaÂdiagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatric Blood and Cancer, 2019, 66, e27652.	1.5	17
35	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
36	Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion–negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2018, 124, 1973-1981.	4.1	14

SIMONE HETTMER

#	Article	IF	CITATIONS
37	Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 327-336.	1.9	13
38	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. Oncology Research and Treatment, 2021, 44, 301-312.	1.2	13
39	Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. British Journal of Cancer, 2021, 124, 1637-1646.	6.4	12
40	Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma. Scientific Reports, 2018, 8, 15674.	3.3	9
41	Cefepimeâ€induced neutropenia in a teenager. Pediatric Blood and Cancer, 2008, 51, 715-716.	1.5	8
42	Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. European Journal of Cancer, 2022, 168, 56-64.	2.8	8
43	Second malignancy risk among pediatric, adolescent, and young adult survivors of fusionâ€positive and fusionâ€negative sarcomas: Results from the SEER database, 1992 through 2012. Cancer, 2016, 122, 3492-3500.	4.1	7
44	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatric Blood and Cancer, 2021, 68, e29267.	1.5	7
45	Breast cancer characteristics and surgery among women with Liâ€Fraumeni syndrome in Germany—A retrospective cohort study. Cancer Medicine, 2021, 10, 7747-7758.	2.8	7
46	Growth inhibition associated with disruption of the actin cytoskeleton by Latrunculin A in rhabdomyosarcoma cells. PLoS ONE, 2020, 15, e0238572.	2.5	6
47	Dermatofibrosarcoma protuberans in children and adolescents: Primary and Relapsed disease—Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS). Journal of Surgical Oncology, 2020, 122, 263-272.	1.7	6
48	Combinatorial effects of azacitidine and trametinib on <i>NRAS</i> â€mutated melanoma. Pediatric Blood and Cancer, 2022, 69, e29468.	1.5	6
49	Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatric Blood and Cancer, 2020, 67, e28095.	1.5	5
50	Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. Journal of Pediatric Hematology/Oncology, 2020, 42, e265-e270.	0.6	5
51	Negative correlation of single-cell <i>PAX3:FOXO1</i> expression with tumorigenicity in rhabdomyosarcoma. Life Science Alliance, 2021, 4, e202001002.	2.8	4
52	Induction of Histiocytic Sarcoma in Mouse Skeletal Muscle. PLoS ONE, 2012, 7, e44044.	2.5	3
53	Distinct Malignant Behaviors of Mouse Myogenic Tumors Induced by Different Oncogenetic Lesions. Frontiers in Oncology, 2015, 5, 50.	2.8	3
54	Hedgehog-driven myogenic tumors recapitulate skeletal muscle cellular heterogeneity. Experimental Cell Research, 2016, 340, 43-52.	2.6	3

4

SIMONE HETTMER

#	Article	IF	CITATIONS
55	Myxoid liposarcoma: it's a hippo's world. EMBO Molecular Medicine, 2019, 11, .	6.9	3
56	Case Report: Hepatic Adenoma in a Child With a Congenital Extrahepatic Portosystemic Shunt. Frontiers in Pediatrics, 2020, 8, 501.	1.9	3
57	ATRT-09. Outcome and therapeutic interventions in relapsed and refractory ATRT – The EU-RHAB perspective. Neuro-Oncology, 2022, 24, i4-i4.	1.2	2
58	Lack of Electron Acceptors Contributes to Redox Stress and Growth Arrest in Asparagine-Starved Sarcoma Cells. Cancers, 2021, 13, 412.	3.7	1
59	Abstract 3122: Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma. , 2021, , .		0
60	Abstract 275: Lack of electron acceptors contributes to redox stress and growth arrest in asparagine-starved sarcoma cells. , 2021, , .		0
61	Abstract 1361: Sarcoma-relevant genetic events identified in a chimeric mouse model of sarcoma in skeletal muscle. , 2012, , .		0
62	In Reply: Comments About Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. Journal of Pediatric Hematology/Oncology, 2021, 43, 116-117.	0.6	0
63	Title is missing!. , 2020, 15, e0238572.		0
64	Title is missing!. , 2020, 15, e0238572.		0
65	Title is missing!. , 2020, 15, e0238572.		0
66	Title is missing!. , 2020, 15, e0238572.		0
67	Title is missing!. , 2020, 15, e0238572.		0
68	Title is missing!. , 2020, 15, e0238572.		0